00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month's gains and losing $291.2 billion in aggregate value. Median losses...
19:28 , Dec 21, 2018 |  BC Week In Review  |  Company News

Lilly licenses Aduoro's STING inhibitors

Eli Lilly and Co. (NYSE:LLY) received an exclusive license from Aduro Biotech Inc. (NASDAQ:ADRO) for its cGAS-STING inhibitor platform to develop immunotherapies for autoimmune and inflammatory diseases. Aduro will receive $12 million up front and...
02:11 , Dec 19, 2018 |  BC Extra  |  Company News

Lilly licenses Aduro’s STING inhibitors

Eli Lilly and Co. (NYSE:LLY) received an exclusive license from Aduro Biotech Inc. (NASDAQ:ADRO) for its cGAS-STING inhibitor platform to develop immunotherapies for autoimmune and inflammatory diseases. Aduro will receive $12 million up front and...
14:10 , Apr 3, 2018 |  BC Innovations  |  Targets & Mechanisms

Sensor sensibility

Zhijian “James” Chen’s discovery of the DNA sensor cGAS revealed the missing link between cytosolic DNA and innate immune activation, paving the way for immunotherapies targeting the cGAS-STING pathway. The lowest-hanging fruit has been in...
12:32 , Apr 3, 2018 |  BC Extra  |  Preclinical News

Lurie Prize awarded for cGAS-STING discovery

The Foundation for the National Institutes of Health (FNIH) announced Tuesday it has awarded this year's Lurie Prize in Biomedical Sciences to Zhijian “James” Chen for the discovery of the cytosolic DNA sensor cGAMP synthase...
01:24 , Jan 18, 2018 |  BC Extra  |  Preclinical News

Chromosomal instability can trigger metastasis via STING activity

A paper published in Nature brings into question the safety and efficacy of activating the transmembrane protein 173 (STING; TMEM173) pathway -- which triggers immune responses in the presence of cytosolic DNA -- in cancers...
01:19 , Jan 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Age-related macular degeneration (AMD) Patient sample, cell culture and mouse studies suggest inhibiting cGAS, CASP4, GSDMD, IFNB1, IFNAR1, IRF3 or STAT2 could help treat geographic atrophy. In tissue samples from patients, levels of cGAS,...
20:05 , Nov 6, 2017 |  BC Extra  |  Preclinical News

Team identifies new targets to treat myocardial infarction

In a paper published Monday in Nature Medicine , researchers from Massachusetts General Hospital and colleagues identified the mechanism behind an elevated immune response after myocardial infarction and suggested interferon regulatory factor 3 (IRF3), interferon...
19:51 , Nov 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Mouse studies suggest inhibiting IRF3, IFNAR1, or cGAS could help treat MI. In infarcted heart tissue from a mouse model of MI, IRF3 expression was higher than in heart tissue from...
19:58 , Sep 26, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer; breast cancer; colorectal cancer Patient sample and mouse studies suggest dual inhibition of miR-25 and miR-93 or promoting cGAS expression could help treat brain, breast and colorectal cancers. In patients, high brain...